Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NR3C2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NR3C2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/NR3C2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NR3C2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/NR3C2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00305223 | Colorectum | FAP | intracellular receptor signaling pathway | 67/2622 | 265/18723 | 6.84e-07 | 3.28e-05 | 67 |
GO:00434014 | Colorectum | FAP | steroid hormone mediated signaling pathway | 41/2622 | 136/18723 | 8.82e-07 | 4.03e-05 | 41 |
GO:00097554 | Colorectum | FAP | hormone-mediated signaling pathway | 51/2622 | 190/18723 | 2.23e-06 | 8.87e-05 | 51 |
GO:00305183 | Colorectum | FAP | intracellular steroid hormone receptor signaling pathway | 34/2622 | 116/18723 | 1.43e-05 | 3.80e-04 | 34 |
GO:00713834 | Colorectum | CRC | cellular response to steroid hormone stimulus | 51/2078 | 204/18723 | 1.67e-08 | 2.79e-06 | 51 |
GO:00305224 | Colorectum | CRC | intracellular receptor signaling pathway | 61/2078 | 265/18723 | 2.00e-08 | 3.23e-06 | 61 |
GO:00434015 | Colorectum | CRC | steroid hormone mediated signaling pathway | 37/2078 | 136/18723 | 1.52e-07 | 1.66e-05 | 37 |
GO:00097555 | Colorectum | CRC | hormone-mediated signaling pathway | 46/2078 | 190/18723 | 2.28e-07 | 2.27e-05 | 46 |
GO:00305184 | Colorectum | CRC | intracellular steroid hormone receptor signaling pathway | 32/2078 | 116/18723 | 7.37e-07 | 4.79e-05 | 32 |
GO:00485455 | Colorectum | CRC | response to steroid hormone | 67/2078 | 339/18723 | 1.77e-06 | 8.92e-05 | 67 |
GO:00485457 | Liver | NAFLD | response to steroid hormone | 75/1882 | 339/18723 | 3.44e-11 | 1.12e-08 | 75 |
GO:00713836 | Liver | NAFLD | cellular response to steroid hormone stimulus | 48/1882 | 204/18723 | 1.50e-08 | 1.83e-06 | 48 |
GO:00305226 | Liver | NAFLD | intracellular receptor signaling pathway | 55/1882 | 265/18723 | 1.39e-07 | 1.03e-05 | 55 |
GO:00097556 | Liver | NAFLD | hormone-mediated signaling pathway | 39/1882 | 190/18723 | 1.15e-05 | 3.58e-04 | 39 |
GO:00434016 | Liver | NAFLD | steroid hormone mediated signaling pathway | 28/1882 | 136/18723 | 1.78e-04 | 3.14e-03 | 28 |
GO:00305185 | Liver | NAFLD | intracellular steroid hormone receptor signaling pathway | 24/1882 | 116/18723 | 4.64e-04 | 6.74e-03 | 24 |
GO:1901224 | Liver | NAFLD | positive regulation of NIK/NF-kappaB signaling | 15/1882 | 69/18723 | 3.09e-03 | 2.77e-02 | 15 |
GO:004854512 | Liver | Cirrhotic | response to steroid hormone | 146/4634 | 339/18723 | 7.87e-14 | 6.76e-12 | 146 |
GO:007138312 | Liver | Cirrhotic | cellular response to steroid hormone stimulus | 90/4634 | 204/18723 | 1.04e-09 | 4.70e-08 | 90 |
GO:003052212 | Liver | Cirrhotic | intracellular receptor signaling pathway | 105/4634 | 265/18723 | 5.44e-08 | 1.69e-06 | 105 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NR3C2 | SNV | Missense_Mutation | rs776434075 | c.1091N>T | p.Thr364Met | p.T364M | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.945) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
NR3C2 | SNV | Missense_Mutation | | c.1220N>C | p.Ser407Thr | p.S407T | | protein_coding | tolerated_low_confidence(0.35) | benign(0.145) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
NR3C2 | SNV | Missense_Mutation | | c.2870N>T | p.Pro957Leu | p.P957L | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
NR3C2 | SNV | Missense_Mutation | | c.1959G>T | p.Lys653Asn | p.K653N | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NR3C2 | SNV | Missense_Mutation | novel | c.2113N>C | p.Glu705Gln | p.E705Q | | protein_coding | tolerated(0.34) | benign(0.09) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NR3C2 | SNV | Missense_Mutation | rs770059383 | c.53N>A | p.Arg18Gln | p.R18Q | | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
NR3C2 | SNV | Missense_Mutation | | c.344C>T | p.Ala115Val | p.A115V | | protein_coding | deleterious_low_confidence(0) | benign(0.21) | TCGA-BH-A0HB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
NR3C2 | SNV | Missense_Mutation | novel | c.834N>A | p.His278Gln | p.H278Q | | protein_coding | tolerated_low_confidence(0.19) | possibly_damaging(0.579) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
NR3C2 | insertion | In_Frame_Ins | novel | c.2097_2098insGTGGCTCACGCCTGTAATCCCAGCACTTTG | p.Pro699_Pro700insValAlaHisAlaCysAsnProSerThrLeu | p.P699_P700insVAHACNPSTL | | protein_coding | | | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
NR3C2 | insertion | Frame_Shift_Ins | novel | c.2218_2219insG | p.Met740SerfsTer4 | p.M740Sfs*4 | | protein_coding | | | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | agonist | CHEMBL1200592 | DESOXYCORTICOSTERONE PIVALATE | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | PMID27551786-Compound-106 | | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | agonist | 135651469 | | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | antagonist | 135651551 | PROGESTERONE | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | antagonist | 135650760 | ONAPRISTONE | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | PROGESTERONE | PROGESTERONE | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | FLUDROCORTISONE | FLUDROCORTISONE | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | KBP-5074 | | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | PMID27551786-Compound-II | | |
4306 | NR3C2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | EPLERENONE | EPLERENONE | |